Senior Management

Alligator Bioscience is guided by a seasoned executive leadership team where CEO Søren Bregenholt and CFO Johan Giléus brings deep commercial and scientific expertise to drive strategic growth and development.

Søren Bregenholt

CEO

• Independent in relation to the Company and its management: No
• Independent in relation to major shareholders: Yes
• Holdings in Alligator: 2,315,434 shares, 1,200,000 warrants in program TO 2023/2026 I and 900,000 warrants in program TO 2024/2027 I.
• Other current positions: Chairman of the board of A Bioscience Incentive AB, Atlas Therapeutics AB, Oblique Therapeutics Ab and Kripthonite Therapeutics Aps.

• Full profile

Johan Giléus

CFO

• Independent in relation to the Company and its management: No
• Independent in relation to major shareholders: Yes
• Holdings in Alligator: 1,100,000 shares (through company).
• Other current positions: Board member of A Bioscience Incentive AB and Atlas Therapeutics AB. Board member and CEO of Giléus Consulting AB and Giléus Invest AB.

• Full profile